Evidence map›Paper›PMID 32179516›Full record

Trial reportBMJ open diabetes research & care2020

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.

Venu Menon, Anirudh Kumar, Divyang R Patel, Julie St John, Jeffrey Riesmeyer, Govinda Weerakkody, Giacomo Ruotolo, Kathy E Wolski, Ellen McErlean, Paul C Cremer and 3 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis.European heart journal. Cardiovascular pharmacotherapy · 2022
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Venu MenonHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA menonv@ccf.org.ORCID 0000-0003-4410-2677
Anirudh KumarHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.ORCID 0000-0002-4413-5439
Divyang R PatelHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Julie St JohnHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Jeffrey RiesmeyerEli Lilly and Company, Indianapolis, Indiana, USA.
Govinda WeerakkodyEli Lilly and Company, Indianapolis, Indiana, USA.
Giacomo RuotoloEli Lilly and Company, Indianapolis, Indiana, USA.
Kathy E WolskiHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Ellen McErleanHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Paul C CremerHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Stephen J NichollsMonash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia.
A Michael LincoffHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Steven E NissenHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Cleveland Clinic · USEli Lilly (United States) · USMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-density lipoprotein (HDL) levels are inversely associated with cardiovascular risk. Cholesteryl ester transfer protein inhibition with evacetrapib results in a marked increase in HDL and reduction in low-density lipoprotein (LDL) levels. We evaluated the impact of treatment with evacetrapib versus placebo in the subset of 8236 patients with diabetes mellitus (DM) enrolled in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes trial. METHODS AND

resultsTime to first occurrence of any component of the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, revascularization, and hospitalization for unstable angina was compared among patients with DM randomized to treatment with evacetrapib (n=4127) or placebo (n=4109) over a median of 26 months of follow-up. The mean baseline LDL at initiation was 80 mg/dL with a mean baseline HDL of 44 mg/dL. In patients with DM, evacetrapib resulted in a 131% mean increase in HDL levels and a 32% mean decrease in LDL at 3 months that was sustained during the course of the trial. At 6 months, hemoglobin A1c (HbA1c) levels were lower with evacetrapib than placebo (7.08% vs 7.15%, p=0.023). Composite event rates were higher in patients with DM than without DM (Kaplan-Meier estimates: 15.2% vs 10.6%, HR 1.46, 95% CI 1.30 to 1.64, p<0.001). In the DM group, event rates for the composite endpoint (14.5% evacetrapib vs 16% placebo, HR 0.95, 95% CI 0.85 to 1.07, p=0.38) and individual components of the composite were similar for both evacetrapib and placebo groups. No significant treatment interaction between treatment assignment and diabetes status was noted.

conclusionDespite a favorable increase in HDL, and decreases in LDL and HbA1c levels in patients with DM, we observed no benefits of treatment with evacetrapib on prespecified clinical outcomes in this high-risk population.

Indexed as

AgedAnticholesteremic AgentsBenzodiazepinesCardiovascular DiseasesCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, LDLDiabetes ComplicationsDiabetes MellitusFemaleHumansHypoglycemic AgentsMaleMiddle AgedTreatment OutcomeAnticholesteremic AgentsBenzodiazepinesCETP protein, humanCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, LDLevacetrapibHypoglycemic Agentscardiovascular complicationscholesteryl ester transfer protein

Identifiers

PMID32179516
PMCPMC7073792
OpenAlexW3010808013

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.